Inderjit Mehmi (@mi_onc) 's Twitter Profile
Inderjit Mehmi

@mi_onc

Medical Oncologist•The Angeles Clinic and Research Institute•Melanoma•Merkel Cell Cancer•Clinical Trial Concierge

ID: 900437878488133636

linkhttp://www.theangelesclinic.org/ calendar_today23-08-2017 19:21:34

626 Tweet

297 Followers

415 Following

C Faith (@abbeyandsmokey) 's Twitter Profile Photo

November 11 Please help support Ocular melanoma research. If you can't make it to event you can donate at the link below. Thank you!

Inderjit Mehmi (@mi_onc) 's Twitter Profile Photo

Just learned Amgen 🧪🔬🧬 increasing price of #onpro supportive care medicine for patient getting chemotherapy. Is that true? #breastcancer #greed<good SABCS

OncLive.com (@onclive) 's Twitter Profile Photo

RP1 + cemiplimab provided a numerical improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, missing the primary end points of the phase 2 CERPASS trial. #Oncology onclive.com/view/rp1-plus-…

Janice Mehnert, MD (@janicem10) 's Twitter Profile Photo

First paper of 2024! In a retrospective analysis, adjuvant therapy appears to benefit patients with acral, but not mucosal, melanoma. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based th… pubmed.ncbi.nlm.nih.gov/38278007/

Justin Moyers (@jtmoyers) 's Twitter Profile Photo

Talking about updates in the world of melanoma at MOASC summit in NB tomorrow! MOASC I’ll be talking about exciting updates in world of melanoma treatment and novel therapeutics in research The Angeles Clinic with Inderjit Mehmi Omid Hamid MD Cancer at Cedars-Sinai !

Talking about updates in the world of melanoma at  MOASC summit in NB tomorrow! <a href="/MOASC_Office/">MOASC</a> 

I’ll be talking about exciting updates in world of melanoma treatment and novel therapeutics in research  <a href="/angelesclinic/">The Angeles Clinic</a> with <a href="/Mi_onc/">Inderjit Mehmi</a> <a href="/OmidHamidMD/">Omid Hamid MD</a>  <a href="/CSCancerCenter/">Cancer at Cedars-Sinai</a> !
NEJM (@nejm) 's Twitter Profile Photo

Presented at #ASCO24: Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: nej.md/3wSo3uk

Presented at #ASCO24: 

Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: nej.md/3wSo3uk
Omid Hamid MD (@omidhamidmd) 's Twitter Profile Photo

The Angeles Clinic we believe in education and discovery. @mi_onc discusses updates in Melanoma Research Foundation hashtag #CureOM in #OcularMelanoma from ASCO youtube.com/watch?v=feJE7s…